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Breast cancer is the commonest cancer in Sudanese women. Reported genetic alterations in the form of mutations
in tumor suppressors are low in frequencies and could not explain the peculiarities of the diseases including its
focal nature. Potential contributors disease aetiology include oncogenic viruses such as Epstein-Barr virus (EBV), an
established culprit of nasopharyngeal carcinoma, one of the most frequent cancers in Sudan.
In this study, DNA was extracted from malignant tissue samples and healthy tumour-free tissue from the same breast.
Polymerase chain Reaction (PCR) was used to amplify two genes encoding for EBV viral proteins. The presence of
Epstein-Barr virus and its cellular localization was confirmed by in situ hybridization (ISH) for Epstein-Barr encoded small
RNAs (EBERs). Given the reported low frequency of mutations in BRCA1 and BRCA2 in Sudanese breast cancer patients,
the methylation status of six tumor suppressor genes was investigated using methylation specific PCR. EBV genome
was detected in 55.5% (n = 90) of breast cancer tissues as compared to 23% in control tissue samples (p = 0.0001).
Using ISH, EBV signal was detected in all 18 breast cancer biopsies examined while all five normal breast tissue biopsies
tested were negative for EBV. Of six tumour suppressor genes investigated BRCA1, BRCA2, and p14 appeared to be
under strong epigenetic silencing.
In conclusion, we present evidence of a strong association between EBV and breast carcinoma in Sudanese patients,
and considerable epigenetic silencing of tumor suppressors that may likely be an outcome or an association with viral
oncogenesis.
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Breast cancer is the most frequent malignancy among
women in Sudan and worldwide. Despite the public
health significance of the condition there are few well
defined risk factors associated with the disease which
could help explain its high incidence.
Infections with oncogenic viruses have been investi-
gated as possible risk factors for breast cancer aetiology
including mouse mammary tumor virus (MMTV),
Epstein-Barr virus (EBV) and human papilloma virus
(HPV) [1]. EBV was the first human virus to be directly
implicated in carcinogenesis. It is a common infection
affecting over 90% of the world’s population [2]. EBV
has been implicated in the pathogenesis of Burkitt’s* Correspondence: mibrahim@iend.org
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reproduction in any medium, provided the orlymphoma, Hodgkin’s disease, non-Hodgkin’s lymph-
oma, nasopharyngeal carcinoma, as well as leiomyosar-
comas arising in immunocompromised individuals [3].
The exact mechanism by which EBV transforms cells is
not fully understood, although it has been suggested that
cell cycle proteins could be the target of such transform-
ation mechanisms [4], akin to other oncogenic viruses.
HPV proteins for instance interact with the cell cycle
proteins p53 [5] and retinoblastoma [6].
In Sudan, breast cancer is characterised by a geograph-
ically focal nature, early onset and aggressive course of
the disease [7]. BRCA1, BRCA2 and p53 mutations are
infrequent in Sudanese breast cancer patients. Epigenetic
changes are suggested as alternative mechanisms to ac-
count for the minor contribution of genetic alterations
in three tumour suppressor genes, BRCA1, BRCA2, and
p53, in both sporadic and familial breast cancer cases in
Sudan [8].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Detection of Epstein- Barr virus in breast cancer
tissues and controls using EBNA-1 and LMP-1 primers
and the P value for the significance of the difference








*Indicates Fisher Exact Test.
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categorized forms of aberrant methylation, hypomethyla-
tion, and hypermethylation [9-11] but the exact mechan-
ism involved is yet to be understood. With or without
viral involvement, the picture seems to be complex
enough; the methylation profiles of tumour suppressor
genes appear to vary according to tumour type, and each
tumour apparently displays a distinct ‘DNA hypermethy-
lome’ [12].
The overall prevalence and endemicity of nasopharyn-
geal carcinoma, another EBV-associated cancer [13-15]
and its high frequency among breast cancer families
(Hamad, personal communication) prompted the current
investigation of a possible association between EBV infec-
tion and breast cancer in Sudan.
Methods
Patients and sampling
92 biopsy specimens of breast carcinoma and 50 matched
normal tissues adjacent to breast tumours were collected
from operated individuals of varying ages from different
hospitals in Khartoum State, Sudan, who had not yet re-
ceived anti-cancer medications. Samples were collected
after signing informed consent forms. The study was ap-
proved by the Ethical Review Committee of the Institute
of Endemic Diseases, University of Khartoum.
All cancer and control tissues were divided into two
parts, one was collected in 10% buffered formalin for
histological examination and in situ hybridization (ISH),
and the second was preserved as fresh tissue at −40°C
for subsequent DNA extraction.
DNA extraction and PCR for EBV
DNA was extracted using the chloroform method. DNA
quality was assessed using 1% agarose gel electrophoresis
and further evaluated in terms of the A260/280 ratio in
a Nanodrop 1000 apparatus. EBV genome was detected
by PCR using two primers that targets EBV nuclear antigen-
4 (EBNA-4) 5′-GAGGAGGAAGACAAGAGTGG and 5′
GATTCAGGCGTGGTCCTTGG 3′ and latent membrane
protein-1 (LMP-1) 5′CCGAAGAGGTTGAAAACAAA3′
and 5′GTGGGGGTCGTCATCATCTC 3′.
In Situ Hybridization for Epstein-Barr encoded small
RNAs (EBERs)
ISH was performed on 5 μm-thick paraffin embedded tis-
sue sections. EBV peptide nucleic acid (PNA) Probe/
Fluorescein (Dako) was used, and the signal was detected
using the PNA ISH detection Kit. Hybridization lasted
1 hour at 55° Celsius (C) and was visualized by alkaline
phosphatase (AP)-conjugated antifluorescein antibodies.
Nitro blue tetrazolium (NBT)/Bromo chloroIndoyl phos-
phate (BCIP) (Dako, Denmark) was used as a substrate for
AP. To test the sensibility of ISH, we used a negative anda positive control provided by the manufacturer, and an
undifferentiated nasopharyngeal carcinoma specimen as a
second positive control. A case was considered positive if
the nucleus of a tumour cell stained dark blue or black.
Methylation based PCR
Two types of PCR that detect methylation status were
employed: a bisulphite conversion based test, followed by
methylation-specific PCR, and an restriction digestion en-
zymatic methylation-sensitive PCR test. Bisulphite conver-
sion was performed using MethylEasy™ Xceed (Human
Genetic Signatures, North Ryde, NSW Australia) according
to the manufacturer’s protocol. Enzymatic methylation-
specific PCR was carried out to confirm the results in a




Ninety two patients were enrolled in this study ranging in
age between 25 and 84 years with a median of 54 years.
Histologically, 25 (27%) patients suffered invasive lobular
carcinoma, 47 (51%) infiltrative ductal carcinoma and 20
(22%) had carcinoma in situ.
EBV detection
EBV genome was detected in 49 (53.3%) and 10 (11%)
patients by LMP-1 and EBNA-4 PCR respectively. In the
control tissues, EBV was detected in 12 (24%) patients
using primers for LMP-1 while all control samples were
negative when EBNA-4 primers were used (Table 1).
Statistical analysis revealed a significant difference be-
tween cancer tissues and controls by both LPM-1 and
EBNA-4 primers (p = 0.0001).
ISH was employed to confirm the presence of the EBV
genome in malignant breast tissue. Using this technique,
EBV was detected in all examined samples (18 biopsies)
and its presence was confined to the malignant cells. In
contrast, all five histologically normal tissues examined
showed no signal for EBV (Figure 1).
Figure 1 Nuclear staining for EBER by in situ hybridization in infiltrative ductal carcisnoma of the breast and control tissues. a. Normal
duct staining for H&E. b. Normal duct negative for Epstein –Barr Virus by ISH for EBER. c. Infiltrative ductal carcinoma with individual cells in the
stroma. d. Infiltrative ductal carcinoma of the breast, malignant cells showing positive Epstein-Barr virus by EBER. Positive signals are seen in the
nuclei of tumor cells, but not in adjacent lymphocytes and normal cell. e. Invasive lobular carcinoma. f. EBV positive signal in tumour cells nucloi.
Table 2 The methylation status of 6 genes namely
BRCA1, BRCA2, p14, P16, hMLH, MGM2, in a sample of
23 breast cancer tissues, 7 colorectal, 3 esophageal and 4
control tissues (Blood)
Gene BRCA1 BRCA2 P14 P16 hMLH MGM2
Cancer Number
hypermethylated
Breast (n = 23) 23 23 22 1 1 1
Colon (n = 7) 4 4 5 3 4 3
Oesophageal (n = 3) 1 1 ND 1 1 0
84% 84% 84% 84% 84% 12%
Control (n = 4) 0 0 0 0 0 0
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The two methylation assays gave identical results in the
subset of samples investigated, 33 tumour tissues and 4
control tissues. The methylation frequencies of the differ-
ent genes were as follows: BRCA1 84%, BRCA2 84%, p14
81%, p16 15%, hMLH 18% and MGMT 12%. DNA ex-
tracted from whole blood samples was non-methylated in
all genes. The methylation status differed between tumour
types, in conformity to the literature. BRCA1 and BRCA2
were predominantly methylated in breast cancer while
p14 was more frequently methylated in oesophageal and
colon cancer samples, ranging in frequency between
33.3% and 70% (Table 2).
Discussion
Infection with EBV virus is a frequent event. However,
the reason why it is able to exert an oncogenic effect on
some individuals while sparing others remains poorly
understood. Factors involved in susceptibility to EBV-
driven oncogenesis include host cell cycle proteins like
p53 and others [16-19]. In this study, the correlation be-
tween breast cancer and the presence of the EBV
genome was investigated. A highly significant positive
correlation was found based on two PCR targets. Severalstudies have investigated this correlation, but reports are
conflicting. The majority of studies document a wide
range of frequencies for the presence of EBV in breast
carcinoma [20]. Among 15 studies using PCR to detect
EBV in breast tumours that we have reviewed, the virus
was identified in a range of 0 to 66% of specimens.
Prevalence was highest when PCR targeted the EBER
and the reiterated BamH1W sequence [20-26], moderate
when the target was LMP1 or EBNA4 [24] and lowest in
investigations of EBNA1 [27,28]. These discrepancies
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extent of the association and the natural causes and dif-
ferences in aetiology between populations. Another
source of variation is the segment of the EBV genome
expressed. Xue et al. amplified EBV DNA in breast can-
cer tissues and used reverse transcriptase (RT) PCR to
confirm expression of BART (BamH1A rightward tran-
scription), LF3, EBNA1, BARF1, and BZLF1, establishing
variation in the ability to detect molecular signals of
presence/expression of these markers in the tumours
[29]. Joshi et al. found that about 55% of breast cancer
cases showed EBNA-1 expression in tumour cells, while
all the controls with benign breast disease demonstrated
no expression [30]. Our results are in agreement with
studies that detected the virus using LMP-1 and EBNA-
4 as targets for amplification.
Discrepancies in detection efficiency may also be due
to technical differences or variation s between breast
cancer subgroups. Generally, PCR is of value in detect-
ing the presence of the virus in a particular neoplasm,
but cannot directly demonstrate the association between
the virus and the particular type of cancer. EBV DNA
may be derived from tumour cells, surrounding stroma,
or infiltrating lymphocytes. To address such concerns
we compared tumour tissue with normal surrounding
tissue from the same individual and furthermore used
ISH to investigate cellular localization of the virus. Using
ISH, we detected the EBV genome in all 18 breast cancer
specimens investigated but could not detect the virus in
healthy breast tissue, a much higher frequency compared
with reports employing ISH. The confinement of viral
DNA to tumour cells as we demonstrate here strongly
suggests a viral contribution to breast cancer aetiology.
A recent transcriptome analysis of EBV host-viral regu-
latory interaction reported both oncogenes and tumor
suppressors like CFOS and BRCA1 to be co-expressed
during lytic phases of the viral replication indicating the
role of EBV viral genome in cellular transformation [31].
The high frequency of EBV in breast cancer tissue, as re-
ported here, might explain the low frequency of mutations
in BRCA1, BRCA2 exon 11 and p53 among breast cancer
patients in Sudan [8]. These findings raise the stakes of
the virus as an environmental and epigenetic culprit in
breast cancer aetiology in Sudanese patients.
In line with these preliminary findings, the methyla-
tion status of 5 tumour suppressor genes (BRCA1,
BRCA2, p14, p16, hMLH and MGM2) was investigated.
The high frequency of epigenetic silencing in BRCA1,
BRCA2, and p14 suggests a potential influence of the
virus on the methylation machinery, an oncogenic
mechanism reported in other cancers but not yet in
breast cancer [32,33]. The methylation of p14 suggests a
possible upstream mechanism that liberates the tumour
genome from the control of p53 and other majortumour suppressors thus annulling or minimizing the
role of gene mutations. This mechanism was originally
proposed by Esteller et al. in colorectal cancer on the
basis of over-representation of p14ARF hypermethyla-
tion in tumours with wild-type p53 compared to tu-
mours harbouring p53 mutations [34]. The existence of
methylation signatures that dictate the transcriptional
status of tumour suppressors or oncogenes as a pre-
requisite for cancer initiation or development is now
commonplace and is believed to shape the biology of
various tumours.
However, the inactivation of p14 does not seem to be
enough to replenish the loss of function of p53 in cancer
pathogenesis given the central network characteristics of
the protein. We recently reported a striking risk associ-
ation between the p53 arginine allele and breast cancer
in Sudanese individuals [35], an unusual example of a
common polymorphism with a major effect (OR= 13).
This polymorphism has a known geographic pattern of a
north South cline [36], which brings into consideration
the geographical conditioning of the association between
EBV and nasopharyngeal carcinoma endemicity, a known
EBV associated tumour, around the tropics [37].
In conclusion, we present unequivocal evidence sup-
porting a major etiologic role for EBV in breast cancer
pathogenesis in Sudanese patients. Our findings prove
the presence of EBV in a high proportion of breast can-
cer samples in Sudanese patients. The localisation of the
virus in malignant cells makes it a likely risk factor and a
possible aetiological agent in breast carcinogenesis. If
such a causal association of EBV with breast cancer is
further established in functional terms, therapeutic im-
plications might follow in light of the recent advances in
EBV vaccination.
Competing interests
Authors declare no competing interests.
Authors’ contributions
ZAY, performed the laboratory and data analysis and contributed to writing
the manuscript; AM A performed the in situ hybridization; ME, AH and MK,
carried out the methylation assays and designed the tests; MAM and HSM,
supervised the laboratory experiments and sampling procedures,
KA; recruited patients and operated on them, AME, performed the
histopathology and supervised the in situ hybridization assays, and KH,
conceived of the study contributed to recruitment of the patients and their
management; ME I designed the study and wrote the manuscript. All
authors read and approved the final manuscript.
Acknowledgments
This work received financial support from the International Agency of
Genetic Engineering and Biotechnology (ICGEB). Project CRP/SUD/10-01).
Author details
1Institute of Endemic Diseases (IEND) Unit of Disease and Diversity, University
of Khartoum Medical Campus, P.O. Box 102, Khartoum, Sudan. 2Faculty of
Medicine, University of Khartoum, Khartoum, Sudan.
Received: 26 June 2013 Accepted: 24 February 2014
Published: 7 March 2014
Yahia et al. Infectious Agents and Cancer 2014, 9:9 Page 5 of 5
http://www.infectagentscancer.com/content/9/1/9References
1. Lawson JS, Heng RB: Viruses and breast cancer. Cancers 2010, 2:752–772.
2. Cohen J: Epstein–Barr virus infection. N Engl J Med 2000, 343:481–492.
3. Niedboitek G, Young L: Epstein-Barr virus persistence and virus-associated
tumours. Lancet 1994, 343:333–335.
4. Benchimol S, Minden M: Virus oncogens and tumor suppressor genes. In
The basic science of oncology 1998. Edited by Tanno IFHR. New York:
McGraw-Hill:77–90.
5. Thomas M, Massimi P, Banks L: HPV-18 E6 inhibits p53 DNA binding
activity regardless of the oligomeric state of p53 or the exact p53
recognition sequence. Oncogene 1996, 1;13(3):471–480.
6. Etahir HAH, El Hassan AM, Ibrahim ME: Contribution of retinoblastoma
LOH and the p53 Arg/Pro polymorphism to cervical cancer. Mol Med
Reports 2012, 6(3):473–476.
7. Khairy GA, Guraya SY, Ahmed ME, Ahmed MA: Bilateral breast cancer.
Incidence, diagnosis and histological patterns. Saudi Med J 2005,
26:612–615.
8. Masri MA, Abdel Seed NM, Fahal AH, Romano M, Baralle F, El Hassan AM,
Ibrahim ME: Minor Role for BRCA2 (exon11) and p53 (Exon 5-9) among
Sudanese breast cancer patients. Breast Cancer Research and Breast Cancer
Res Treat 2002, J,71(2):145–147.
9. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57–70.
10. Jones PA, Baylin SB: The fundamental role of epigenetics in cancer. Nat
Rev Genet 2002, 3:415–428.
11. Feinberg AP, Tycko B: The history of cancer epigenetics. Nat Rev Cancer
2004, 4:1–11.
12. Esteller M: Aberrant DNA methylation as a cancer inducing mechanism.
Annu Rev Pharmacol Toxicol 2005, 45:629–656. Mol. Genet,16, 50-59.
13. Hidayatalla A, Malik MOE, Hadi AE, Osman AA, Hutt MS: Studies on
nasopharyngeal carcinoma in the Sudan I. epidemiology and aetiology.
Eur J Cancer Clin Oncol 1983, 19:705–1.
14. Abuidris DO, Elgaili EM, Elhaj AH, Elmustafa OM: Histopathological patterns
of nasopharyngeal carcinoma in Sudan. Saudi Med J 2008, 29:962–965.
15. Abdullah NE, Adam AAM, Khalifa EH, El Hassan LA, LAM I, KM H, El Hassan
AM: Nasopharyngeal Cancer in Sudan: epidemiology, clinical and
histological characteristics. Clinical Medicine Insights: Ear, Nose and Throat
2011, 4:5–11.
16. Gregory CD, Dive C, Henderson S, Smith CA, Williams GT, Gordon J,
Rickinson AB: Activation of Epstein-Barr virus latent genes protects
human B cells from death by apoptosis. Nature 1991, 349:612–614.
17. Ishii H, Tamauchi H, Gobe CG: In the absence of Epstein-Barr virus
infection, phorbol ester modulates apoptosis in cycloheximide-treated
Burkitt’s lymphoma (BJA-B) cells. Int J Exp Pathol 1997, 78:123–131.
18. Mauser A, Saito S, Appella E, Anderson CW, Seaman WT, Kenney S: The
Epstein-Barr virus immediate–early protein BZLF1 regulates p53 function
through multiple mechanisms. J Virol 2002, 76:12503–12512.
19. Iamaroon A, Pongsiriwet S, Mahanupab P, Kitikamthon R, Pintong J: Oral
non-Hodgkin lymphomas: studies of EBV and p53 expression. Oral Dis
2003, 9:14–18.
20. Labrecque LG, Barnes DM, Fentiman IS, Griffin BE: Epstein-Barr virus in
epithelial cell tumors: a breast cancer study. Cancer Res 1995, 55:39–45.
21. Horiuchi K, Mishima K, Ohsawa M, Aozasa K: Carcinoma of stomach and
breast with lymphoid stroma: localisation of Epstein- Barr virus. J Clin
Pathol 1994, 47:538–540.
22. Luqmani YA, Shousha S: Presence of Epstein-Barr virus in breast
carcinoma. Int J Oncol 1995, 6:899–903.
23. Bonnet M, Guinebretiere JM, Kremmer E, Grunewald V, Benhamou E,
Contesso G, Joab I: Detection of Epstein-Barr virus in invasive breast
cancers. J Natl Cancer Inst 1999, 91:1376–1381.
24. Brink AATP, van den Brule AJC, van Diest P, Meijer CJLM: Detection of
Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst 2000,
92:655–656.
25. Fina F, Romain S, Ouafik LH, Palmari J, Ben Ayed F, Benharkat S, Bonnier P,
Spyratos F, Foekens JA, Rose C, Buisson M, Gérard H, Reymond MO,
Seigneurin JM, Martin PM: Frequency and genome load of Epstein-Barr
virus in 509 breast cancers from different geographical areas. Br J Cancer
2001, 84:783–790.
26. Grinstein S, Preciado M, Gattuso P, Chabay PA, Warren WH, De Matteo E,
Gould VE: Demonstration of Epstein- Barr virus in carcinomas of various
sites. Cancer Res 2002, 62:4876–4878.27. Gaffey MJ, Frierson HF, Mills SE, Boyd JC, Zarbo RJ, Simpson JF, Gross LK,
Weiss LM: Medullary carcinoma of the breast. Identification of
lymphocyte subpopulations and their significance. Mod Pathol 1993,
6:721–728.
28. McCall SA, Lichy JH, Bijwaard KE, Aguilera NS, Chu WS, Taubenberger JK:
Epstein-Barr virus detection in ductal carcinoma of the breast. J Natl
Cancer Inst 2001, 93:148–150.
29. Xue SA, Lampert IA, Haldane JS, Bridger JE, Griffin BE: Epstein-Barr virus
gene expression in human breast cancer: protagonist or passenger. Br J
Cancer 2003, 89:113–119.
30. Joshi D, Quadri M, Gangane N, Joshi R, Gangane N: Association of Epstein
Barr Virus Infection (EBV) with breast cancer in rural Indian women. PLoS
ONE 2009, 4;4(12):e8180.
31. Arvey A, Tempera I, Tsai K, Chen H, Tikhmyanova N, Klichinsky M, Leslie C,
Lieberman PM: An atlas of the Epstein-Barr virus transcriptome and
Epigenome reveals host -virus regulatory interaction. Cell Host and
Microbe 2012, 12:233–245.
32. Ryan JL, Jones RJ, Kenney SC, Rivenbark AG, Tang W, Knight ERW, Colem
WB, Gulley ML: Epstein-Barr virus-specific methylation of human genes in
gastric cancer cells. Infectious Agents and Cancer 2010, 5:27.
33. Xia L, Tang X, Zhang S, Wang Y, Wang X, Zhao C, Luo B: Methylation and
expression of retinoblastoma and transforming growth
Factor- Genes in Epstein-Barr Virus- Associated and -Negative
Gastric Carcinomas. Gastroenterol Res Pract 2012, 17:1–8.
34. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman
JG: Hypermethylation-associated inactivation of p14ARF is independent
of p16INK4a methylation and p53 mutational status. Cancer Res 2000,
60:129–133.
35. Eltahir HA, Adam AAM, Yahia ZA, Ali NF, Mursi DM, Higazi AM, Eid NA,
Elhassan M, Mohammed S, Ibrahim ME: Codon 72 arginine/proline
polymorphism and cancer in Sudan. Mol Bio Rep 2012, 39(12):10833-6.
doi:10.10.
36. Bereir RH, Mohamed HS, Seleistad M, El Hassan AM, Khalil EAG, Peacock CS,
Blackwell JM, Ibrahim ME: Allele frequency and genotypedistribution of
polymorphisms within within disease-related genes in is influenced by
ethnic population sub-structuring. Genetica 2003, 119(1):57–63.
37. Zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Hele G, Clifford P,
Santesson L: EBV DNA in biopsies of Burkitt tumours and anaplastic
carcinomas of the nasopharynx. Nature 1970, 228:1056–1058.
doi:10.1186/1750-9378-9-9
Cite this article as: Yahia et al.: Epstein Barr virus: a prime candidate of
breast cancer aetiology in Sudanese patients. Infectious Agents and
Cancer 2014 9:9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
